Related Experiment Videos
[Molecular markers as basis for chemotherapy?].
J Brabender1, H J Lenz, P V Danenberg
1USC/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, USA.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|February 24, 2001
Summary
Predicting chemotherapy response in cancer patients is crucial. Analyzing gene expression in tumor biopsies, specifically for thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase, can identify patients likely to respond to 5-fluorouracil treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Context:
- Standard chemotherapy regimens are administered to all cancer patients, irrespective of predicted response, due to the lack of predictive biomarkers.
- Identifying non-responders before treatment can prevent ineffective therapies and associated toxicities.
Purpose:
- To evaluate the utility of quantitative gene expression analysis in pretreatment tumor biopsies for predicting patient response to chemotherapy.
- To establish a rational basis for selecting optimal cancer therapies based on individual tumor biochemistry.
Summary:
- Studies focused on predicting response to 5-fluorouracil (5-FU) in colorectal cancer.
- Quantitative analysis of thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydropyrimidine dehydrogenase (DPD) gene expression levels in tumor tissue.
- Combined analysis of TS, TP, and DPD expression effectively identified patients who would respond to 5-FU therapy, utilizing PCR-enhanced methods on pretreatment biopsies.
Impact:
- Enables personalized medicine by identifying patients likely to benefit from specific chemotherapies.
- Facilitates the selection of effective treatment strategies, improving patient outcomes and reducing செலவு.
- Advances the field of predictive oncology through the application of molecular diagnostics in clinical practice.